194 related articles for article (PubMed ID: 10347978)
1. Therapeutic vaccines for preventing AIDS: their use with HAART.
Hoff R; McNamara J
Lancet; 1999 May; 353(9166):1723-4. PubMed ID: 10347978
[No Abstract] [Full Text] [Related]
2. Immunisation with gp160 in HIV-1 infection.
Pontesilli O; Aiuti F
Lancet; 1999 Sep; 354(9182):948-9. PubMed ID: 10489977
[No Abstract] [Full Text] [Related]
3. HIV-1 matrix protein p17: a candidate antigen for therapeutic vaccines against AIDS.
Fiorentini S; Giagulli C; Caccuri F; Magiera AK; Caruso A
Pharmacol Ther; 2010 Dec; 128(3):433-44. PubMed ID: 20816696
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic T-cell recognition of HIV proteins and peptides.
Nixon DF; McMichael AJ
AIDS; 1991 Sep; 5(9):1049-59. PubMed ID: 1718319
[No Abstract] [Full Text] [Related]
5. Recombinant glycoprotein vaccines for human immunodeficiency virus-infected children and their effects on viral quasispecies.
Essajee SM; Yogev R; Pollack H; Greenhouse B; Krasinski K; Borkowsky W
Clin Diagn Lab Immunol; 2002 Jan; 9(1):79-82. PubMed ID: 11777833
[TBL] [Abstract][Full Text] [Related]
6. Long-term memory B-cell responses in recipients of candidate human immunodeficiency virus type 1 vaccines.
Evans TG; Frey S; Israel H; Chiu J; El-Habib R; Gilbert P; Gaitan A; Montefiori DC;
Vaccine; 2004 Jun; 22(20):2626-30. PubMed ID: 15193388
[TBL] [Abstract][Full Text] [Related]
7. Immunisation with gp160 in HIV-1 infection.
Fiala C; Stewart GT
Lancet; 1999 Sep; 354(9182):948; author reply 949. PubMed ID: 10489976
[No Abstract] [Full Text] [Related]
8. Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators.
Birx DL; Loomis-Price LD; Aronson N; Brundage J; Davis C; Deyton L; Garner R; Gordin F; Henry D; Holloway W; Kerkering T; Luskin-Hawk R; McNeil J; Michael N; Foster Pierce P; Poretz D; Ratto-Kim S; Renzullo P; Ruiz N; Sitz K; Smith G; Tacket C; Thompson M; Tramont E; Yangco B; Yarrish R; Redfield RR
J Infect Dis; 2000 Mar; 181(3):881-9. PubMed ID: 10720508
[TBL] [Abstract][Full Text] [Related]
9. Just (don't) do it.
Schooley RT
J Clin Invest; 1993 Aug; 92(2):535. PubMed ID: 8349794
[No Abstract] [Full Text] [Related]
10. Proliferative responses to human immunodeficiency virus type 1 (HIV-1) gp120 peptides in HIV-1-infected individuals immunized with HIV-1 rgp120 or rgp160 compared with nonimmunized and uninfected controls.
Sitz KV; Ratto-Kim S; Hodgkins AS; Robb ML; Birx DL
J Infect Dis; 1999 Apr; 179(4):817-24. PubMed ID: 10068576
[TBL] [Abstract][Full Text] [Related]
11. [Anti-HIV-1 p17 antibody as anti-HIV agent].
Tsuchie H; Tochikura A; Kageyama S; Kurimura T
Nihon Rinsho; 1993 Sep; 51 Suppl():213-8. PubMed ID: 8271386
[No Abstract] [Full Text] [Related]
12. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.
Dis Markers; 1991; 9(1):51. PubMed ID: 1742945
[No Abstract] [Full Text] [Related]
13. HIV gp160 vaccine gene therapy (Wyeth-Lederle Vaccines-Malvern).
Drugs R D; 1999 Jun; 1(6):451-2. PubMed ID: 10566081
[No Abstract] [Full Text] [Related]
14. [The virus can not yet be eradicated. "HIV-infected patients cannot be completely cured"].
Hellbom K
Krankenpfl J; 1998; 36(7-8):274. PubMed ID: 9775853
[No Abstract] [Full Text] [Related]
15. Vaccines. Monkey puzzles.
Cohen J
Science; 2002 Jun; 296(5577):2325-6. PubMed ID: 12089425
[No Abstract] [Full Text] [Related]
16. HIV-1/AIDS vaccine development: are we in the darkness.
Qiu C; Xu JQ
Chin Med J (Engl); 2008 May; 121(10):939-45. PubMed ID: 18706210
[No Abstract] [Full Text] [Related]
17. India targets local HIV strain in test of AIDS vaccine.
Jayaraman KS
Nature; 2004 Jan; 427(6971):185. PubMed ID: 14724601
[No Abstract] [Full Text] [Related]
18. Prime-boost strategies in DNA vaccines.
Dale CJ; Thomson S; De Rose R; Ranasinghe C; Medveczky CJ; Pamungkas J; Boyle DB; Ramshaw IA; Kent SJ
Methods Mol Med; 2006; 127():171-97. PubMed ID: 16988455
[TBL] [Abstract][Full Text] [Related]
19. Is an effective HIV vaccine feasible?
Cohen J
Science; 2005 Jul; 309(5731):99. PubMed ID: 15994545
[No Abstract] [Full Text] [Related]
20. Immunological aspects of patients with HIV-1 disease following immunization with recombinant gp160 (VaxSyn).
Guerra E; Ricci G; Carlesimo M; Varani AR; Pontesilli O; Scala E; Mezzaroma I; Pierdominici ; Pandolfi F; Antinori A; De Luca A; Murri R; Ammassari A; Ortona L; Aiuti F
Antibiot Chemother (1971); 1996; 48():147-54. PubMed ID: 8726519
[No Abstract] [Full Text] [Related]
[Next] [New Search]
